BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 33178839)

  • 21. PD-1+ TIM-3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer.
    Nakano M; Ito M; Tanaka R; Yamaguchi K; Ariyama H; Mitsugi K; Yoshihiro T; Ohmura H; Tsuruta N; Hanamura F; Sagara K; Okumura Y; Nio K; Tsuchihashi K; Arita S; Kusaba H; Akashi K; Baba E
    Cancer Sci; 2018 Sep; 109(9):2986-2992. PubMed ID: 30187676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma.
    Cai C; Xu YF; Wu ZJ; Dong Q; Li MY; Olson JC; Rabinowitz YM; Wang LH; Sun Y
    World J Urol; 2016 Apr; 34(4):561-7. PubMed ID: 26253654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone.
    Rajnai H; Heyning FH; Koens L; Sebestyén A; Andrikovics H; Hogendoorn PC; Matolcsy A; Szepesi Á
    Virchows Arch; 2014 Feb; 464(2):229-39. PubMed ID: 24306958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas.
    Li Z; Liu X; Guo R; Wang P
    Tumour Biol; 2017 May; 39(5):1010428317698352. PubMed ID: 28475007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-expression of TIM-3 and CEACAM1 promotes T cell exhaustion in colorectal cancer patients.
    Zhang Y; Cai P; Li L; Shi L; Chang P; Liang T; Yang Q; Liu Y; Wang L; Hu L
    Int Immunopharmacol; 2017 Feb; 43():210-218. PubMed ID: 28038383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-expression of PD-1 with TIGIT or PD-1 with TIM-3 on tumor-infiltrating CD8
    Meyiah A; Mahmoodi Chalbatani G; Al-Mterin MA; Malekraeisi MA; Murshed K; Elkord E
    Int Immunopharmacol; 2023 Jun; 119():110207. PubMed ID: 37099940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune-Checkpoint Blockade Opposes CD8
    Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
    Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma.
    Kawashima A; Kanazawa T; Kidani Y; Yoshida T; Hirata M; Nishida K; Nojima S; Yamamoto Y; Kato T; Hatano K; Ujike T; Nagahara A; Fujita K; Morimoto-Okazawa A; Iwahori K; Uemura M; Imamura R; Ohkura N; Morii E; Sakaguchi S; Wada H; Nonomura N
    Sci Rep; 2020 Apr; 10(1):6220. PubMed ID: 32277125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
    Giraldo NA; Becht E; Vano Y; Petitprez F; Lacroix L; Validire P; Sanchez-Salas R; Ingels A; Oudard S; Moatti A; Buttard B; Bourass S; Germain C; Cathelineau X; Fridman WH; Sautès-Fridman C
    Clin Cancer Res; 2017 Aug; 23(15):4416-4428. PubMed ID: 28213366
    [No Abstract]   [Full Text] [Related]  

  • 30. Tumor antigen-specific CD8
    Lu X; Yang L; Yao D; Wu X; Li J; Liu X; Deng L; Huang C; Wang Y; Li D; Liu J
    Cell Immunol; 2017 Mar; 313():43-51. PubMed ID: 28110884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-15 induces strong but short-lived tumor-infiltrating CD8 T cell responses through the regulation of Tim-3 in breast cancer.
    Heon EK; Wulan H; Macdonald LP; Malek AO; Braunstein GH; Eaves CG; Schattner MD; Allen PM; Alexander MO; Hawkins CA; McGovern DW; Freeman RL; Amir EP; Huse JD; Zaltzman JS; Kauff NP; Meyers PG; Gleason MH; Overholtzer MG; Wiseman SS; Streutker CD; Asa SW; McAlindon TP; Newcomb PO; Sorensen PM; Press OA
    Biochem Biophys Res Commun; 2015 Aug; 464(1):360-6. PubMed ID: 26141233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Up-regulation of TIM-3 on CD4+ tumor infiltrating lymphocytes predicts poor prognosis in human non-small-cell lung cancer].
    Ji P; Chen D; Bian J; Xia R; Song X; Wen W; Zhang X; Zhu Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jun; 31(6):808-11. PubMed ID: 26062425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1.
    Hladíková K; Partlová S; Koucký V; Bouček J; Fonteneau JF; Zábrodský M; Tachezy R; Grega M; Špíšek R; Fialová A
    Oral Oncol; 2018 Jul; 82():75-82. PubMed ID: 29909905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma.
    Keane C; Law SC; Gould C; Birch S; Sabdia MB; Merida de Long L; Thillaiyampalam G; Abro E; Tobin JW; Tan X; Xu-Monette ZY; Young KH; Gifford G; Gabreilli S; Stevenson WS; Gill A; Talaulikar D; Jain S; Hernandez A; Halliday SJ; Bird R; Cross D; Hertzberg M; Gandhi MK
    Blood Adv; 2020 Apr; 4(7):1367-1377. PubMed ID: 32267932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumoural Pellino-1 expression and Pellino-1-expressive cytotoxic T-cells are associated with poor prognosis in diffuse large B-cell lymphoma.
    Shin SJ; Ko J; Hwang HS; Huh J; Lee CW; Lee JK; Go H
    Pathology; 2024 Apr; 56(3):374-381. PubMed ID: 38296676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tim-3 mediates T cell trogocytosis to limit antitumor immunity.
    Pagliano O; Morrison RM; Chauvin JM; Banerjee H; Davar D; Ding Q; Tanegashima T; Gao W; Chakka SR; DeBlasio R; Lowin A; Kara K; Ka M; Zidi B; Amin R; Raphael I; Zhang S; Watkins SC; Sander C; Kirkwood JM; Bosenberg M; Anderson AC; Kuchroo VK; Kane LP; Korman AJ; Rajpal A; West SM; Han M; Bee C; Deng X; Schebye XM; Strop P; Zarour HM
    J Clin Invest; 2022 May; 132(9):. PubMed ID: 35316223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lower PTEN may be associated with CD8+ T cell exhaustion in diffuse large B-cell lymphoma.
    Zheng S; Ma J; Li J; Pang X; Ma M; Ma Z; Cui W
    Hum Immunol; 2023 Oct; 84(10):551-560. PubMed ID: 37481380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased PD-1
    Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
    Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8
    Kim HD; Park S; Jeong S; Lee YJ; Lee H; Kim CG; Kim KH; Hong SM; Lee JY; Kim S; Kim HK; Min BS; Chang JH; Ju YS; Shin EC; Song GW; Hwang S; Park SH
    Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer.
    Sawada M; Goto K; Morimoto-Okazawa A; Haruna M; Yamamoto K; Yamamoto Y; Nakagawa S; Hiramatsu K; Matsuzaki S; Kobayashi E; Kawashima A; Hirata M; Iwahori K; Kimura T; Ueda Y; Kimura T; Wada H
    Int Immunol; 2020 May; 32(6):397-405. PubMed ID: 32009163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.